Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
The increase in adiponectin levels in obese patients with untreated dyslipidemia and its mRNA expression in adipose tissue of obese animals are one of the most interesting consequences of rimonabant treatment. Thus, part of rimonabant's metabolic effects could be related to an enhancement of adiponectin secretion and its consequence on the modulation of insulin action, as well as energy homeostasis. The present study investigated the effects of rimonabant in adiponectin knockout mice (Ad(-/-)) exposed to diet-induced obesity conditions. Six-week-old Ad(-/-) male mice and their wild-type littermate controls (Ad(+/+)) were fed a high-fat diet for 7 mo. During the last month, animals were administered daily either with vehicle or rimonabant by mouth (10 mg/kg). High-fat feeding induced weight gain by about 130% in both wild-type and Ad(-/-) mice. Obesity was associated with hyperinsulinemia and insulin resistance. Treatment with rimonabant led to a significant and similar decrease in body weight in both Ad(+/+) and Ad(-/-) mice compared with vehicle-treated animals. In addition, rimonabant significantly improved insulin sensitivity in Ad(+/+) mice compared with Ad(+/+) vehicle-treated mice by decreasing hepatic glucose production and increasing glucose utilization index in both visceral and subcutaneous adipose tissue. In contrast, rimonabant failed to improve insulin sensitivity in Ad(-/-) mice, despite the loss in body weight. Rimonabant's effect on body weight appeared independent of the adiponectin pathway, whereas adiponectin seems required to mediate rimonabant-induced improvement of insulin sensitivity in rodents.
Migrenne
Stéphanie
S
University Paris-Diderot, Paris Diderot-Bâtiment Buffon, Paris Cedex 13, France. stephanie.migrenne@univ-paris-diderot.fr
Lacombe
Amélie
A
Lefèvre
Anne-Laure
AL
Pruniaux
Marie-Pierre
MP
Guillot
Etienne
E
Galzin
Anne-Marie
AM
Magnan
Christophe
C
D052242:Adiponectin / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D004041:Dietary Fats; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D005951:Glucose Tolerance Test; D006946:Hyperinsulinism / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D010880:Piperidines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D000077285:Rimonabant; D050151:Subcutaneous Fat / Q000187:drug effects / Q000378:metabolism; D015431:Weight Loss / Q000187:drug effects*
D052242:Adiponectin; C499919:Adipoq protein, mouse; D019440:Anti-Obesity Agents; D004041:Dietary Fats; D007328:Insulin; D008055:Lipids; D010880:Piperidines; D011720:Pyrazoles; D005947:Glucose; D000077285:Rimonabant